As of Jan. 5, 2024, four stocks in the financial sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis.
Dermata Therapeutics shares jumped 57.3% to $0.9601 in pre-market trading.
The Dow Jones index closed higher by around 10 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Biopharma company Atai Life Sciences (NASDAQ: ATAI) shared positive results from a Phase 1 clinical study on MDMA R-enantiomer, EMP-01, under development for the potential treatment of PTSD.
Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI) has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing short-duration psychedelics for neuropsychiatric conditions.
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining over 100 points on Thursday.
The Dow traded up 0.33% to 37,554.56 while the NASDAQ fell 0.10% to 14,578.04. The S&P 500 also rose, gaining, 0.09% to 4,708.93.
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<